1 results match your criteria: "Institute of Biochemistry of Federal Research Center for Fundamental and Translational Medicine[Affiliation]"
Cardiovasc Hematol Disord Drug Targets
January 2022
Institute of Biochemistry of Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russian Federation.
Medicinal preparations currently used for the treatment of patients with chronic cardiac failure involve those that reduce the heart load (vasodilators, diuretics, beta-blockers, and angiotensin- converting enzyme (ACE) inhibitors). Cardiotonic drugs with the cAMP-dependent mechanism are unsuitable for long-term administration due to the intensification of metabolic processes and an increase in the oxygen demand of the myocardium and all tissues of the body. For many years, digoxin has remained the only preparation enhancing the efficiency of myocardial performance.
View Article and Find Full Text PDF